Cargando…

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females

Osteoporosis is a condition in which bone mineral density is reduced due to altered bone microstructure, which results in increased skeletal fragility and incidence of various types of fractures. Adipokines such as chemerin, vaspin, omentin-1 and osteoprotegerin are involved in bone remodeling. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Tariq, Saba, Tariq, Sundus, Abualhamael, Shahad Abduljalil, Shahzad, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864312/
https://www.ncbi.nlm.nih.gov/pubmed/35222038
http://dx.doi.org/10.3389/fphar.2022.822671
_version_ 1784655436439355392
author Tariq, Saba
Tariq, Sundus
Abualhamael, Shahad Abduljalil
Shahzad, Muhammad
author_facet Tariq, Saba
Tariq, Sundus
Abualhamael, Shahad Abduljalil
Shahzad, Muhammad
author_sort Tariq, Saba
collection PubMed
description Osteoporosis is a condition in which bone mineral density is reduced due to altered bone microstructure, which results in increased skeletal fragility and incidence of various types of fractures. Adipokines such as chemerin, vaspin, omentin-1 and osteoprotegerin are involved in bone remodeling. The current study was designed to determine the changes in circulating chemerin, vaspin, omentin-1, and osteoprotegerin levels after treatment with oral ibandronate 150 mg in postmenopausal osteoporotic females. The present study enrolled 107 postmenopausal osteoporotic females from a tertiary care hospital in Faisalabad, Pakistan, based on stringent inclusion and exclusion criteria. Sixty-six healthy postmenopausal, non-osteoporotic females with no systemic illness were chosen from the general population. The assessment of bone mineral density (BMD) was done using a DEXA scan. Serum levels of chemerin, vaspin, omentin-1 and osteoprotegerin were estimated using commercially available enzyme-linked immunosorbent assay kits. The collected data were analyzed with the Statistical Package for Social Sciences (SPSS) version 24. Following 6 months of ibandronate treatment, there was a significant decrease of 24.24% (p < .033) in serum chemerin levels, as well as a significant increase in serum vaspin levels 343.32% (p < .001) and osteoprotegerin levels 19.57% (p < .001), with no significant change in omentin-1 levels. Thus, an increase in serum chemerin levels and a decrease in serum vaspin and osteoprotegerin levels could be implicated in osteoporosis.
format Online
Article
Text
id pubmed-8864312
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88643122022-02-24 Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females Tariq, Saba Tariq, Sundus Abualhamael, Shahad Abduljalil Shahzad, Muhammad Front Pharmacol Pharmacology Osteoporosis is a condition in which bone mineral density is reduced due to altered bone microstructure, which results in increased skeletal fragility and incidence of various types of fractures. Adipokines such as chemerin, vaspin, omentin-1 and osteoprotegerin are involved in bone remodeling. The current study was designed to determine the changes in circulating chemerin, vaspin, omentin-1, and osteoprotegerin levels after treatment with oral ibandronate 150 mg in postmenopausal osteoporotic females. The present study enrolled 107 postmenopausal osteoporotic females from a tertiary care hospital in Faisalabad, Pakistan, based on stringent inclusion and exclusion criteria. Sixty-six healthy postmenopausal, non-osteoporotic females with no systemic illness were chosen from the general population. The assessment of bone mineral density (BMD) was done using a DEXA scan. Serum levels of chemerin, vaspin, omentin-1 and osteoprotegerin were estimated using commercially available enzyme-linked immunosorbent assay kits. The collected data were analyzed with the Statistical Package for Social Sciences (SPSS) version 24. Following 6 months of ibandronate treatment, there was a significant decrease of 24.24% (p < .033) in serum chemerin levels, as well as a significant increase in serum vaspin levels 343.32% (p < .001) and osteoprotegerin levels 19.57% (p < .001), with no significant change in omentin-1 levels. Thus, an increase in serum chemerin levels and a decrease in serum vaspin and osteoprotegerin levels could be implicated in osteoporosis. Frontiers Media S.A. 2022-02-09 /pmc/articles/PMC8864312/ /pubmed/35222038 http://dx.doi.org/10.3389/fphar.2022.822671 Text en Copyright © 2022 Tariq, Tariq, Abualhamael and Shahzad. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Tariq, Saba
Tariq, Sundus
Abualhamael, Shahad Abduljalil
Shahzad, Muhammad
Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
title Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
title_full Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
title_fullStr Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
title_full_unstemmed Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
title_short Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
title_sort effect of ibandronate therapy on serum chemerin, vaspin, omentin-1 and osteoprotegerin (opg) in postmenopausal osteoporotic females
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864312/
https://www.ncbi.nlm.nih.gov/pubmed/35222038
http://dx.doi.org/10.3389/fphar.2022.822671
work_keys_str_mv AT tariqsaba effectofibandronatetherapyonserumchemerinvaspinomentin1andosteoprotegerinopginpostmenopausalosteoporoticfemales
AT tariqsundus effectofibandronatetherapyonserumchemerinvaspinomentin1andosteoprotegerinopginpostmenopausalosteoporoticfemales
AT abualhamaelshahadabduljalil effectofibandronatetherapyonserumchemerinvaspinomentin1andosteoprotegerinopginpostmenopausalosteoporoticfemales
AT shahzadmuhammad effectofibandronatetherapyonserumchemerinvaspinomentin1andosteoprotegerinopginpostmenopausalosteoporoticfemales